Novus Biologicals launches Histone Deacetylase Antibodies

Novus released seven antibodies belonging to the HDAC protein family. These antibodies include: HDAC1 Antibody (NBP1-44097), HDAC5 Antibody (NBP1-44093), HDAC4 Antibody (NBP1-44094), HDAC7 Antibody (NBP1-44092), HDAC2 Antibody (NBP1-44095), HDAC2 Antibody (NBP1-44096), HDAC11 Antibody (NBP1-44267). These antibodies cross-react in a variety of species and all have been positively validated for use in Western blot and ELISA.

Histone deacetylases (HDACS) play a crucial role in gene expression. Acetylation is one type of post-translational modification of histones that strongly influences the regulation of gene transcription. HDACs are enzymes that catalyze the removal of acetyl groups from lysine residues on histones, resulting in transcriptional suppression. HDACs are expressed in many diverse tissues and can function in the nucleus or cytosol. HDACs also are involved with cell differentiation, growth arrest and death.

These new antibodies represent different components of the histone deacetylase complex. All components contribute to histone deactylation, however each possesses other functions depending on its localization in the cell and with which proteins it reacts. HDAC1 interacts with retinoblastoma tumor-supressor protein, and this complex deacetylates p53 yielding apoptotic effects. HDAC5 interacts with MEF2A in order to suppress MEF2A-dependent genes; HDAC5 has been shown to be associated with colon cancer. HDAC4 acts with histone acetyltransferases in order to control core histone acetylation. HDAC7 is part of many transcriptional corepressor complexes that can target specific promoters to achieve deacetylation.  HDAC2 has been implicated to interact with YY1 and together contribute to transcriptional regulation by tethering RPD3 to DNA as a cofactor. HDAC11 modifies histone octomers which package DNA into dense chromatin to hinder gene expression.

HDACs have been associated with oncological, epigenetic, and chromatin research. Each of Novus’ new HDAC antibodies has been mentioned in at least one publication. For more information, visit the individual datasheets.


For more information on these new HDAC antibodies or to inquire about product collaborations, please contact the Novus Product Development Team by calling 303-730-1950 or via e-mail at


Release Date: 
Tuesday, July 13, 2010 - 06:00